Objective To investigate the expression of immunoscore and PD-L1 in hepatocellular carcinoma(HCC), and to analyze the relationship between the expression of PD-L1 and immunoscore and the clinicopathological characteristics and prognosis of HCC. Methods Immunohistochemical staining was used to detect the expression of immunoscore and PD-L1 in 61 cases of hepatocellular carcinoma tissue, and to analyze the relationship between the expression of immunoscore and PD-L1 in hepatocellular carcinoma and different clinicopathological features and prognosis．Results The expression rate of high-immunoscore was 26.2%, the low-immunoscore expression rate was 73.8%. In clinical indicators，the positive expression rate of immunoscore was negatively related to patient's preoperative AFP level (P<0.005), and intrahepatic recurrence (P<0.05), but not to factors of patient’s age, gender, tumor size, differentiation, and non-vascular invasion correlated (P>0.05). Kaplan–Meier analysis presented that the immunoscore showed good stratification between high-immunoscore and low-immunoscore groups in both overall survival (P<0.01) and progression-free survival (P<0.01), respectively. The positive expression rate of PD-L1 in hepatocellular carcinoma was 44.3%, which was significantly higher than that in normal control group (P<0.01).Kaplan-Meier analysis presented that the PD-L1-positive patients was significantly lower in patients with negative PD-L1-negative patients. In clinical indicators，the positive expression rate of PD-L1 was negatively related to patient’s immunoscore (P<0.01)．Conclusions The expression of immunoscore can be used as an important prognostic maker for patients with hepatocellular carcinoma. Patients with high-immunoscore are significantly associated with a prolonged OS and PFS, however patients with low-immunoscore are more likely to occur early recurrence, prognosis is even worse. The positive expression rate of PD-L1 is negatively related to patient’s immunoscore.
Key words
Immunoscore /
PD-L1 /
Prognosis /
Hepatocellular carcinoma
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] Nagtegaal ID, Quirke P, Schmoll HJ. Has the new TNM classification for colorectal cancer improved care[J]. Nat Rev Clin Oncol, 2011, 9(2): 119-123. DOI: 10.1038/nrclinonc.2011.157.
[2] 孙成, 田志刚. 免疫评分: 依据肿瘤组织免疫特性进行预后预测[J]. 中国肿瘤生物治疗杂志, 2015, 22(2): 177-182. DOI: 10.3872/j.issn.1007-385X.2015.2.007.
[3] Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome[J]. Science, 2006, 313(5795): 1960-1964. DOI: 10.1126/science.1129139.
[4] Pagès F, Mlecnik B, Marliot F, et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study[J]. Lancet, 2018, 391(10135): 2128-2139. DOI: 10.1126/science.1129139. DOI: 10.1016/S0140-6736(18)30789-X.
[5] Ding W, Xu XZ, Qian Y, et al. Prognostic value of tumor-infiltrating lymphocytes in hepatocellular carcinoma a meta-analysis[J]. Medicine (Baltimore), 2018, 97(50): e13301. DOI: 10.1097/MD. 000000000001 3301.
[6] Yao W, He JC, Yang Y, et al. The prognostic value of tumor-infiltrating lymphocytes in hepatocellular carcinoma: a systematic review and meta-analysis[J]. Sci Rep, 2017, 7(1): 7025. DOI: 10.1038/s41598-017-08128-1.
[7] Cheng CH, Lee CF, Wu TH, et al. Evaluation of the new AJCC staging system for resectable hepatocellular carcinoma. World J Surg Oncol, 2011, 9: 114. DOI: 10.1186/1477-7819-9-114.
[8] 丛文铭, 步宏, 陈杰, et al. 原发性肝癌规范化病理诊断指南(2015年版). 解放军医学杂志, 2015, 40(11): 865-872. DOI:10.11855/j.issn.0577-7402.2015.11.03.
[9] Parpart S, Roessler S, Dong F, et al. Modulation of miR-29 expression by alpha-fetoprotein is linked to the hepatocellular carcinoma epigenome[J]. Hepatology, 2014, 60(3): 872-883. DOI: 10.1002/hep.27200.
[10]Marshall A, Alexander G. Vascular invasion leaves its mark in hepatocellular carcinoma[J]. J Hepatol, 2011, 55(6): 1174-1175. DOI: 10.1016/j.jhep.2011.05.005.
[11] Shah SA, Cleary SP, Wei AC, et al. Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes[J]. Surgery, 2007, 141(3): 330-339. DOI: 10.1016/j.surg.2006.06.028.
[12]Mlecnik B, Bindea G, Angell HK, et al. Integrative analyses of colorectal cancer show immunoscore is a stronger predictor of patient survival than microsatellite instability[J]. Immunity, 2016, 44(3): 698-711. DOI: 10.1016/j.immuni.2016.02.025.
[13]Anitei MG, Zeitoun G, Mlecnik B, et al. Prognostic and predictive values of the immunoscore in patients with rectal cancer[J]. Clin Cancer Res, 2014, 20(7): 1891-1899. DOI: 10.1158/1078-0432.CCR-13-2830.
[14] Galon J, Mlecnik B, Bindea G, et al. Towards the introduction of the 'Immunoscore' in the classification of malignant tumours[J]. J Pathol, 2014, 232(2): 199-209. DOI: 10.1002/path.4287.
[15] Gabrielson A, Wu YN, Wang HK, et al. Intratumoral CD3 and CD8 T-cell densities associated with relapse-free survival in HCC[J]. Cancer Immunol Res, 2016, 4(5): 419-430. DOI: 10.1158/2326-6066.CIR-15-0110.
[16] Sun C, Xu J, Song JX, et al. The predictive value of centre tumour CD8(+) T cells in patients with hepatocellular carcinoma: comparison with immunoscore[J]. Oncotarget, 2015, 6(34): 35602-35615. DOI: 10.18632/oncotarget.5801.
[17]Novikova MV, Khromova NV, Kopnin PB. Components of the hepatocellular carcinoma microenvironment and their role in tumor progression[J]. Biochemistry (Mosc), 2017, 82(8): 861-873. DOI: 10.1134/S0006297917080016.
